INNOVIVA INC. news, videos and press releases
For more news please use our advanced search feature.
INNOVIVA INC. - More news...
INNOVIVA INC. - More news...
- Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
- Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
- Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
- Innoviva to Participate in the Citi 2024 Global Healthcare Conference
- Innoviva to Participate in the UBS Global Healthcare Conference
- Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
- Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
- Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
- Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
- Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Innoviva Announces Retirement of Board Chairman
- Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
- Innoviva Stock Trading Halted Today
- Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
- Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
- Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
- Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
- Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
- Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
- Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
- Innoviva Completes Acquisition of Entasis Therapeutics
- Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
- Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
- Shareholder Alert: Ademi LLP investigates whether Entasis Therapeutics Holdings Inc. has obtained a Fair Price in its transaction with Innoviva
- Innoviva to Acquire Entasis Therapeutics
- Innoviva Reports First Quarter 2022 Financial Results
